Xenon Pharmaceuticals has been added to the Russell 3000 and Russell 2000 Indexes, effective June 27, 2025.
Quiver AI Summary
Xenon Pharmaceuticals Inc. has announced its inclusion in the Russell 3000® and Russell 2000® Indexes as of June 27, 2025, as part of the annual reconstitution. The Russell 3000® Index tracks the performance of the largest 3,000 U.S. stocks by market capitalization, while the Russell 2000® Index focuses on the smallest 2,000 companies within that group. This inclusion highlights Xenon's status as a small-cap company and is significant for investment managers and institutional investors, as approximately $10.6 trillion in assets are indexed to Russell U.S. indexes. Xenon, dedicated to developing innovative therapeutics for neurological conditions, is advancing treatments such as Azetukalner, a selective Kv7 potassium channel opener, targeting high unmet medical needs like epilepsy and depression.
Potential Positives
- Xenon Pharmaceuticals has been added to the prestigious Russell 3000® and Russell 2000® Indexes, enhancing its visibility in the market.
- Inclusion in the Russell 2000® Index can attract more institutional investors and index fund investments, potentially increasing stock liquidity and value.
- The Russell U.S. Indexes manage approximately $10.6 trillion in assets, indicating significant market recognition for Xenon Pharmaceuticals through this inclusion.
Potential Negatives
- Inclusion in the Russell 2000® Index may indicate that the company is perceived as a smaller, less stable investment compared to companies in larger indices, potentially affecting investor perception.
- The reliance on indices for investment may expose Xenon Pharmaceuticals to volatility based on broader market trends that are out of their control.
- Without additional information on their financial health or product pipeline, the press release does not provide a clear context for the company's recent performance or outlook, which could raise concerns among investors.
FAQ
What is the significance of Xenon Pharmaceuticals being added to the Russell 3000® Index?
Xenon Pharmaceuticals' inclusion in the Russell 3000® Index enhances its visibility to investors and indicates strong market performance.
When did Xenon Pharmaceuticals join the Russell 2000® Index?
Xenon Pharmaceuticals became part of the Russell 2000® Index on June 27, 2025, during the annual reconstitution.
What does the Russell 2000® Index represent?
The Russell 2000® Index measures the performance of the 2,000 smallest companies within the broader Russell 3000® Index.
How are Russell U.S. Indexes used by investors?
Investment managers use Russell U.S. Indexes as benchmarks for investment strategies and to create index funds, managing approximately $10.6 trillion in assets.
What is Xenon Pharmaceuticals focused on?
Xenon Pharmaceuticals specializes in developing therapeutics for neurological conditions, including treatments for epilepsy and depression.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$XENE Insider Trading Activity
$XENE insiders have traded $XENE stock on the open market 5 times in the past 6 months. Of those trades, 0 have been purchases and 5 have been sales.
Here’s a breakdown of recent trading of $XENE stock by insiders over the last 6 months:
- IAN MORTIMER (PRESIDENT & CEO) has made 0 purchases and 4 sales selling 55,000 shares for an estimated $2,213,996.
- STEVEN GANNON sold 3 shares for an estimated $91
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$XENE Hedge Fund Activity
We have seen 82 institutional investors add shares of $XENE stock to their portfolio, and 109 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DEEP TRACK CAPITAL, LP added 830,868 shares (+491.3%) to their portfolio in Q1 2025, for an estimated $27,875,621
- FMR LLC added 762,209 shares (+10.1%) to their portfolio in Q1 2025, for an estimated $25,572,111
- LOGOS GLOBAL MANAGEMENT LP added 650,000 shares (+inf%) to their portfolio in Q1 2025, for an estimated $21,807,500
- BAKER BROS. ADVISORS LP removed 646,271 shares (-65.0%) from their portfolio in Q1 2025, for an estimated $21,682,392
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 640,845 shares (-44.6%) from their portfolio in Q1 2025, for an estimated $21,500,349
- CAPITAL INTERNATIONAL INVESTORS added 541,520 shares (+21.3%) to their portfolio in Q1 2025, for an estimated $18,167,996
- FIRST LIGHT ASSET MANAGEMENT, LLC removed 532,676 shares (-45.9%) from their portfolio in Q1 2025, for an estimated $17,871,279
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$XENE Analyst Ratings
Wall Street analysts have issued reports on $XENE in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- RBC Capital issued a "Outperform" rating on 05/13/2025
- Wells Fargo issued a "Overweight" rating on 05/13/2025
To track analyst ratings and price targets for $XENE, check out Quiver Quantitative's $XENE forecast page.
Full Release
VANCOUVER, British Columbia and BOSTON, June 27, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company has been added to the broad-market Russell 3000® and small-cap Russell 2000® Indexes as part of the annual reconstitution, effective at the close of U.S. equity markets on Friday, June 27, 2025.
The Russell 3000® Index is an equity index that tracks the performance of the largest 3,000 U.S. stocks by market capitalization. The Russell 2000® Index measures the performance of the 2,000 smallest companies within the Russell 3000® Index. Inclusion in the Russell 2000® results in automatic inclusion in the appropriate growth and value style indexes.
Russell U.S. Indexes are widely used by investment managers and institutional investors as the basis for index funds and as benchmarks for investment strategies. Approximately $10.6 trillion in assets are benchmarked against Russell U.S. indexes.
For more information on the Russell 3000® Index and the Russell indexes reconstitution, go to the “Russell Reconstitution” section on the FTSE Russell website.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. We are advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. For more information, please visit www.xenon-pharma.com .
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Contacts:
For Investors:
Chad Fugere
Vice President, Investor Relations
(857) 675-7275
[email protected]
For Media:
Colleen Alabiso
Senior Vice President, Corporate Affairs
(617) 671-9238
[email protected]
